Castle Biosciences, Inc. · NASDAQ:CSTL

Castle Biosciences — FY2025 Earnings Presentation

7 slides from Castle Biosciences's earnings presentation, January 2026

  1. Slide 1: Empowering people, informing care decisions

    Empowering people, informing care decisions Preliminary Unaudited Fourth Quarter and Year-End Results 2025 January 2026 ©2026 Castle Biosciences 1

  2. Slide 2: Disclaimers

    Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sectio

  3. Slide 3: Registered Trademarks and Preliminary Results

    Registered Trademarks DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Preliminary Results Castle Biosciences has not completed the pr

  4. Slide 4: Clinical portfolio and pipeline tests

    Clinical portfolio and pipeline tests ~U.S. TAM1/Use Franchise Test Indication/Utility Discovery Development Commercial Population Cutaneous melanoma/ ~$540M/ risk of sentinel lymph node positivity, 130k patients w/ recurrence & metastasis invasive CM Cutaneous squamous cell carcinoma/ ~$820M/ risk

  5. Slide 5: Preliminary Fourth Quarter and Year-end 2025 Performance Results (unaudited)

    Preliminary Fourth Quarter and Year-end 2025 Performance Results1 (unaudited) 4Q25 4Q24 2025 2024 Expected to exceed $340 million, Revenue To be $332.1 million $86.3 million above the previously guided announced range of $327-335 million2 Cash, cash equivalents & As of 12/31/25 marketable investment

  6. Slide 6: Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results Highlights

    Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results Highlights1 1 Total test reports for our core revenue drivers (DecisionDx-Melanoma, 1 TissueCypher) increased 42% in Q4 2025 year over year, driving 37% growth for full year 2025 Achieved provided guidance of high single-digit percentag

  7. Slide 7: Thank You

    Thank You ©2026 Castle Biosciences 7

Castle Biosciences — FY2025 Earnings Presentation on 6ix